Abstract:Breast cancer is a major disease with high morbidity and mortality in women worldwide. Increased use of imaging biomarkers has been shown to add more information with clinical utility in the detection and evaluation of breast cancer. To date, numerous studies related to PET-based imaging in breast cancer have been published. Here, we review available studies on the clinical utility of different PET-based molecular imaging methods in breast cancer diagnosis, staging, distant-metastasis detection, therapeutic and prognostic prediction, and evaluation of therapeutic responses. For primary breast cancer, PET/MRI performed similarly to MRI but better than PET/CT. PET/CT and PET/MRI both have higher sensitivity than MRI in the detection of axillary and extra-axillary nodal metastases. For distant metastases, PET/CT has better performance in the detection of lung metastasis, while PET/MRI performs better in the liver and bone. Additionally, PET/CT is superior in terms of monitoring local recurrence. The progress in novel radiotracers and PET radiomics presents opportunities to reclassify tumors by combining their fine anatomical features with molecular characteristics and develop a beneficial pathway from bench to bedside to predict the treatment response and prognosis of breast cancer. However, further investigation is still needed before application of these modalities in clinical practice. In conclusion, PET-based imaging is not suitable for early-stage breast cancer, but it adds value in identifying regional nodal disease and distant metastases as an adjuvant to standard diagnostic imaging. Recent advances in imaging techniques would further widen the comprehensive and convergent applications of PET approaches in the clinical management of breast cancer.

Recent Advances in Radiotracers Targeting Novel Cancer-Specific Biomarkers in China: A Brief Overview

China’s Radiopharmaceuticals on Expressway: 2014–2021

Radionuclide-based Theranostics - a Promising Strategy for Lung Cancer.

Recent Advances in Emerging Radiopharmaceuticals and the Challenges in Radiochemistry and Analytical Chemistry

Inspired by Novel Radiopharmaceuticals: Rush Hour of Nuclear Medicine.

Recent Advances in Molecular Image-Guided Cancer Radionuclide Therapy.

Recent progress of nuclear medicine evaluation of curative effect of 223Ra dichloride treatment on castration-resistant prostate cancer and bone metastases

Current status and future perspective of radiopharmaceuticals in China

Growing research and development of targeted anticancer drugs in China

Molecular Imaging and Therapy of Cancer with Radiolabeled Nanoparticles.

Positron emission tomography imaging of lung cancer: An overview of alternative positron emission tomography tracers beyond F18 fluorodeoxyglucose

Nanoscale Radiotheranostics for Cancer Treatment: From Bench to Bedside

Recent Advances in Pretargeted Strategy for Cancer Theranostics.

Radiomics and radiogenomics for precision radiotherapy

CD146‐targeted Nuclear Medicine Imaging in Cancer: State of the Art

Current status of contemporary diagnostic radiotracers in the management of breast cancer: first steps toward theranostic applications

Enhancing X‐Ray Sensitization with Multifunctional Nanoparticles

New Radiotracers for Imaging of Vascular Targets in Angiogenesis-Related Diseases.

Progress and Future Trends in PET/CT and PET/MRI Molecular Imaging Approaches for Breast Cancer

Recent Advances in Pretargeted Imaging of Tumors in Vivo

Novel CDK19-Targeted Radiotracers: A Potential Design Strategy to Improve the Pharmacokinetics and Tumor Uptake